NASDAQ:INO 7 December 2025

INO Stock: Inovio’s FDA BLA Milestone, New Equity Offerings and 2026 Catalyst – Latest News and Forecasts (December 7, 2025)

Inovio Pharmaceuticals closed at $2.07 on December 5, up 2.5% for the day and nearly 20% over the past 10 sessions, with volume near 1 million shares. The stock recently crossed its 200-day moving average, while short interest remains high at 34% of daily volume. Wall Street’s average 12-month price target is $9, despite continued losses and minimal revenue.

7 December 2025

Biotechnology·Financial Forecasts·NASDAQ:INO·Stock Market

CAFO.PA Oversold Bounce Setup at €7.92 on EURONEXT
March 19, 2026, 9:20 PM EDT. CAFO.PA stock trades at €7.92 pre-market on EURONEXT, near its yearly low of €7.42 after a 6.82% drop over five days. The stock shows an oversold bounce opportunity amid thin volume of 46 shares versus a 50-day average of 787, signaling a fragile rebound. With a market cap of €72.8 million, trailing PE of 4.92 indicates deep value compared to its sector, which averages a PE of 19.27. Price sits just below the 200-day moving average, near support at €7.42 and resistance at €8.04, favoring mean-reversion trades. Risks include geographical concentration and weak interest coverage, with limited catalysts ahead. Traders should apply strict risk management, using limit orders and tight stops given low liquidity. Meyka AI assigns a HOLD rating with a score of 68.71, reflecting measured upside potential.